tiprankstipranks
Advertisement
Advertisement

PVLA Stock Latest News

Palvella Reports Positive Phase 3 Data for QTORIN
Company AnnouncementsPalvella Reports Positive Phase 3 Data for QTORIN
25m ago
8K
PVLA
Palvella Therapeutics announces new data from SELVA, TOIVA studies
PremiumThe Fly
Palvella Therapeutics announces new data from SELVA, TOIVA studies
2h ago
PVLA
Palvella Unveils Promising Phase 2 Data for QTORIN
PremiumCompany Announcements
Palvella Unveils Promising Phase 2 Data for QTORIN
5d ago
8K
PVLA
Palvella Therapeutics announces new data from TOIVA trial of Qtorin
PremiumThe Fly
Palvella Therapeutics announces new data from TOIVA trial of Qtorin
5d ago
PVLA
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market
PremiumCompany Announcements
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market
7d ago
8K
PVLA
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
PremiumRatingsAnalyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
9d ago
PVLA
Palvella Therapeutics initiated with an Overweight at Stephens
Premium
The Fly
Palvella Therapeutics initiated with an Overweight at Stephens
9d ago
PVLA
Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year
Premium
The Fly
Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year
13d ago
PVLA
Palvella Highlights QTORIN Progress and Financing in Q1 Update
PremiumCompany Announcements
Palvella Highlights QTORIN Progress and Financing in Q1 Update
13d ago
8K
PVLA
Palvella Therapeutics doses first patients in LOTU trial
PremiumThe Fly
Palvella Therapeutics doses first patients in LOTU trial
16d ago
PVLA
Palvella Therapeutics Adds Independent Dermatology Expert to Board
PremiumCompany Announcements
Palvella Therapeutics Adds Independent Dermatology Expert to Board
1M ago
8K
PVLA
Palvella Showcases QTORIN Platform Momentum and Commercial Readiness
PremiumCompany Announcements
Palvella Showcases QTORIN Platform Momentum and Commercial Readiness
1M ago
8K
PVLA
3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
2M ago
KOD
PVLA
De-Risked SELVA Trial Success and Scalable QTORIN Platform Underpin Buy Rating on Palvella
Premium
Ratings
De-Risked SELVA Trial Success and Scalable QTORIN Platform Underpin Buy Rating on Palvella
2M ago
PVLA
Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway
Premium
Ratings
Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway
2M ago
PVLA
Palvella Therapeutics price target raised to $240 from $210 at Chardan
PremiumThe Fly
Palvella Therapeutics price target raised to $240 from $210 at Chardan
2M ago
PVLA
Palvella Therapeutics price target raised to $210 from $200 at Oppenheimer
PremiumThe Fly
Palvella Therapeutics price target raised to $210 from $200 at Oppenheimer
2M ago
PVLA
Palvella Highlights 2025 Results and SELVA Phase 3 Progress
PremiumCompany Announcements
Palvella Highlights 2025 Results and SELVA Phase 3 Progress
2M ago
8K
PVLA
PVLA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
PVLA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
PVLA
Palvella Therapeutics price target raised to $270 from $255 at H.C. Wainwright
PremiumThe FlyPalvella Therapeutics price target raised to $270 from $255 at H.C. Wainwright
2M ago
PVLA
Buy Rating Driven by Strong Phase 3 SELVA Data and Favorable FDA Pathway for QTORIN in Rare MLM Indication
Premium
Ratings
Buy Rating Driven by Strong Phase 3 SELVA Data and Favorable FDA Pathway for QTORIN in Rare MLM Indication
2M ago
PVLA
Palvella Therapeutics announces European patent covering anhydrous compositions
Premium
The Fly
Palvella Therapeutics announces European patent covering anhydrous compositions
2M ago
PVLA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >